Allergan signage at the NYSE
Brendan McDermid | Reuters
The agreement is expected to be worth $188 a share in cash and stock, according to the report. At that price, it would represent a 45% premium above Allergan’s Monday closing price of $129.57.
Allergan’s shares soared more than 33% in premarket trading following the report. Shares of AbbVie were down more than 5%.
This story is developing. Please check back for updates.